Literature DB >> 17414316

The new B7s: playing a pivotal role in tumor immunity.

Dallas B Flies1, Lieping Chen.   

Abstract

B7-H1, B7-DC, B7-H2, B7-H3, and B7-H4, all new additions to the B7 family, here termed "the new B7s," are emerging as important tools in directing immune function; each with unique, yet often overlapping functions. Clearly, each B7 molecule has developed its own indispensable niche in the immune system. The expression of both stimulatory and inhibitory B7 molecules seems to play an essential role in regulating the immune response to transformed cells through a variety of mechanisms. As specific niches of B7 family members continue to be dissected, their diagnostic and therapeutic potential becomes ever more apparent. In this review, we will discuss the role of the new B7s in activation and inhibition of antitumor immune responses, their prospects in diagnostics, and also potential and developing immunotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414316     DOI: 10.1097/CJI.0b013e31802e085a

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  76 in total

Review 1.  Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.

Authors:  Hironori Uruga; Mari Mino-Kenudson
Journal:  Virchows Arch       Date:  2021-01-24       Impact factor: 4.064

2.  Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.

Authors:  Takaaki Arigami; Yoshikazu Uenosono; Sumiya Ishigami; Takahiko Hagihara; Naoto Haraguchi; Shoji Natsugoe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

3.  Tissue Acquisition in Clinical Trials-Essential for Progress.

Authors:  S Percy Ivy; Jeffrey S Abrams
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

Review 4.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

5.  Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.

Authors:  Elaine Bigelow; Katherine M Bever; Haiying Xu; Allison Yager; Annie Wu; Janis Taube; Lieping Chen; Elizabeth M Jaffee; Robert A Anders; Lei Zheng
Journal:  J Vis Exp       Date:  2013-01-03       Impact factor: 1.355

Review 6.  Adding fuel to the fire: immunogenic intensification.

Authors:  Geraldine O'Sullivan Coyne; James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Authors:  Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

Review 8.  The complex role of B7 molecules in tumor immunology.

Authors:  Barbara Seliger; Francesco M Marincola; Soldano Ferrone; Hinrich Abken
Journal:  Trends Mol Med       Date:  2008-11-03       Impact factor: 11.951

9.  CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Authors:  Juan R Cubillos-Ruiz; Diana Martinez; Uciane K Scarlett; Melanie R Rutkowski; Yolanda C Nesbeth; Ana L Camposeco-Jacobs; Jose R Conejo-Garcia
Journal:  Oncotarget       Date:  2010-09

10.  Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.

Authors:  Kory L Alderson; Qing Zhou; Vanessa Berner; Danice E C Wilkins; Jonathan M Weiss; Bruce R Blazar; Lisbeth A Welniak; Robert H Wiltrout; Doug Redelman; William J Murphy
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.